Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphatic Vessels | 1 | 2023 | 356 | 0.650 |
Why?
|
Radiography, Interventional | 1 | 2024 | 1131 | 0.560 |
Why?
|
Lymphedema | 1 | 2023 | 527 | 0.550 |
Why?
|
Tattooing | 1 | 2016 | 57 | 0.530 |
Why?
|
Radiology, Interventional | 1 | 2020 | 483 | 0.500 |
Why?
|
Sarcoidosis | 1 | 2016 | 535 | 0.360 |
Why?
|
Embolization, Therapeutic | 1 | 2020 | 1401 | 0.340 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2018 | 3670 | 0.300 |
Why?
|
Tomography, X-Ray Computed | 2 | 2024 | 20762 | 0.300 |
Why?
|
Lung Neoplasms | 3 | 2024 | 13586 | 0.300 |
Why?
|
Lung | 1 | 2024 | 10101 | 0.260 |
Why?
|
Antineoplastic Agents | 2 | 2018 | 13677 | 0.230 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2016 | 2195 | 0.230 |
Why?
|
Lymphography | 1 | 2023 | 189 | 0.210 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5341 | 0.210 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2018 | 9419 | 0.200 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2018 | 5432 | 0.200 |
Why?
|
Lymphatic System | 1 | 2023 | 251 | 0.200 |
Why?
|
Pneumothorax | 1 | 2024 | 393 | 0.180 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9262 | 0.170 |
Why?
|
Single-Cell Analysis | 3 | 2018 | 2540 | 0.140 |
Why?
|
Thoracic Neoplasms | 1 | 2018 | 269 | 0.130 |
Why?
|
Choice Behavior | 2 | 2013 | 848 | 0.130 |
Why?
|
Sequence Analysis, DNA | 2 | 2018 | 4786 | 0.130 |
Why?
|
Hydrazines | 1 | 2017 | 223 | 0.130 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2018 | 388 | 0.120 |
Why?
|
Reward | 2 | 2013 | 981 | 0.120 |
Why?
|
Insurance Claim Review | 1 | 2018 | 744 | 0.110 |
Why?
|
Amygdala | 2 | 2013 | 1379 | 0.110 |
Why?
|
Reaction Time | 1 | 2020 | 2101 | 0.110 |
Why?
|
Sequence Analysis, RNA | 2 | 2018 | 2040 | 0.110 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 1667 | 0.100 |
Why?
|
Lymph Nodes | 1 | 2023 | 3474 | 0.100 |
Why?
|
Triazoles | 1 | 2017 | 904 | 0.100 |
Why?
|
Fatal Outcome | 1 | 2016 | 1836 | 0.100 |
Why?
|
Conditioning, Operant | 1 | 2013 | 308 | 0.090 |
Why?
|
Cluster Analysis | 1 | 2018 | 2732 | 0.090 |
Why?
|
Gene Frequency | 1 | 2018 | 3623 | 0.090 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2017 | 820 | 0.090 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2017 | 1099 | 0.080 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2048 | 0.080 |
Why?
|
Feedback | 1 | 2013 | 799 | 0.080 |
Why?
|
Physical Exertion | 1 | 2011 | 668 | 0.080 |
Why?
|
Retrospective Studies | 4 | 2024 | 81760 | 0.070 |
Why?
|
Insurance Coverage | 1 | 2018 | 1946 | 0.070 |
Why?
|
Cell Nucleus | 1 | 2016 | 2885 | 0.070 |
Why?
|
Neoadjuvant Therapy | 1 | 2018 | 2907 | 0.070 |
Why?
|
Cues | 1 | 2011 | 878 | 0.060 |
Why?
|
Survival Analysis | 1 | 2018 | 10099 | 0.060 |
Why?
|
Frontal Lobe | 1 | 2011 | 1426 | 0.060 |
Why?
|
Quality Improvement | 1 | 2020 | 3857 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2018 | 2931 | 0.060 |
Why?
|
Genotype | 1 | 2018 | 13045 | 0.050 |
Why?
|
Middle Aged | 5 | 2024 | 223487 | 0.050 |
Why?
|
Ibotenic Acid | 2 | 2013 | 59 | 0.050 |
Why?
|
Postoperative Complications | 1 | 2024 | 15833 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2017 | 10478 | 0.050 |
Why?
|
Rats, Long-Evans | 2 | 2013 | 380 | 0.050 |
Why?
|
Humans | 9 | 2024 | 768171 | 0.050 |
Why?
|
Aged | 4 | 2024 | 171502 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2016 | 4058 | 0.050 |
Why?
|
Male | 7 | 2024 | 364731 | 0.040 |
Why?
|
Discrimination Learning | 2 | 2013 | 278 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2018 | 22290 | 0.040 |
Why?
|
Female | 6 | 2024 | 397187 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2016 | 6395 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 11878 | 0.030 |
Why?
|
Ketones | 1 | 2017 | 183 | 0.030 |
Why?
|
Furans | 1 | 2017 | 202 | 0.030 |
Why?
|
Excitatory Amino Acid Agonists | 1 | 2013 | 142 | 0.030 |
Why?
|
Reversal Learning | 1 | 2013 | 57 | 0.030 |
Why?
|
Doxorubicin | 1 | 2017 | 2234 | 0.020 |
Why?
|
Microinjections | 1 | 2011 | 322 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2016 | 2916 | 0.020 |
Why?
|
Food Preferences | 1 | 2013 | 398 | 0.020 |
Why?
|
Maze Learning | 1 | 2011 | 482 | 0.020 |
Why?
|
Regression Analysis | 1 | 2018 | 6340 | 0.020 |
Why?
|
Adult | 3 | 2018 | 223646 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 3612 | 0.020 |
Why?
|
Photic Stimulation | 1 | 2013 | 1997 | 0.020 |
Why?
|
Rats | 2 | 2013 | 23782 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2013 | 6229 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2018 | 59626 | 0.010 |
Why?
|
Survival Rate | 1 | 2016 | 12840 | 0.010 |
Why?
|
Prefrontal Cortex | 1 | 2013 | 2238 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11244 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 10397 | 0.010 |
Why?
|
Apoptosis | 1 | 2017 | 9527 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 9540 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 17142 | 0.010 |
Why?
|
Medicare | 1 | 2018 | 6809 | 0.010 |
Why?
|
Phenotype | 1 | 2017 | 16726 | 0.010 |
Why?
|
Animals | 3 | 2017 | 169285 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 30009 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2016 | 39354 | 0.010 |
Why?
|
Time Factors | 1 | 2016 | 40220 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 60066 | 0.010 |
Why?
|
United States | 1 | 2018 | 73039 | 0.010 |
Why?
|
Mice | 1 | 2017 | 82049 | 0.010 |
Why?
|
Concepts
(99)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(10)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_